Amgen and UCB, a Brussels, Belgium-based biopharmaceutical company, have submitted a biologics license application to the US Food and Drug Administration for romosozumab, an investigational monoclonal antibody for treating osteoporosis. Romosozumab binds and inhibits sclerostin, a protein naturally occurring in the bone to increase bone formation and decrease bone resorption.

Source: Amgen